Contrasting Effects of Diazepam and Repeated Restraint Stress on Latent Inhibition in Mice
Overview
Psychology
Social Sciences
Affiliations
The effects on latent inhibition (LI; a delay in conditioning when a CS has been pre-exposed without consequences) of repeated restraint stress and the anxiolytic drug diazepam were examined in C57BL/6 mice to know whether previous aversive events or anxiolysis are factors determining the expression of LI. The LI model was optimized for this strain particularly sensitive to stress (using both the CER and the conditioned freezing procedures) and characterized with typical (haloperidol) and atypical (clozapine and olanzapine) antipsychotic drugs administered either during the conditioning or the pre-exposure phases. An acute challenge with amphetamine, a dopamine releaser, was done to verify the enhancement of hyperactivity in C57BL/6 mice after the restraint stress sensitization. At all doses tested, diazepam decreased latent inhibition when administered during the pre-exposure phase (similarly to atypical antipsychotic drugs). Repeated restraint stress enhanced LI by blocking the CS-induced freezing in pre-exposed mice. In contrast, pre-treatment with diazepam before pre-exposure allowed the expression of CS-induced freezing in stressed mice pre-exposed to the tone. It is suggested that stress and anxiolytic drugs can have opposite effects on attention or perseveration processes during learning of conflicting contingency responses.
Reward devaluation disrupts latent inhibition in fear conditioning.
De La Casa L, Mena A, Ruiz-Salas J, Quintero E, Papini M Learn Behav. 2017; 46(1):49-59.
PMID: 28699100 DOI: 10.3758/s13420-017-0282-1.
Developmental vitamin D deficiency and schizophrenia: the role of animal models.
Schoenrock S, Tarantino L Genes Brain Behav. 2015; 15(1):45-61.
PMID: 26560996 PMC: 4768902. DOI: 10.1111/gbb.12271.
Attentional processing in C57BL/6J mice exposed to developmental vitamin D deficiency.
Harms L, Turner K, Eyles D, Young J, McGrath J, Burne T PLoS One. 2012; 7(4):e35896.
PMID: 22563415 PMC: 3338544. DOI: 10.1371/journal.pone.0035896.
Bay-Richter C, OTuathaigh C, OSullivan G, Heery D, Waddington J, Moran P Int J Neuropsychopharmacol. 2008; 12(3):403-14.
PMID: 19012810 PMC: 2760776. DOI: 10.1017/S1461145708009656.